Update shared on 24 Nov 2025
Collegium Pharmaceutical’s analyst price target remains unchanged at $46.80, as analysts point to a balanced outlook where revisions to profit margin and future P/E estimates offset each other.
What's in the News
- Collegium Pharmaceutical raised its 2025 net product revenue guidance and now expects a range of $775 to $785 million, up from the previous range of $745 million to $760 million (Key Developments).
- The company reported no share repurchases from July 1, 2025 to September 30, 2025. The completed buyback resulted in 0 shares repurchased and $0 million spent during this period (Key Developments).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $46.80.
- Discount Rate is virtually flat, declining marginally from 6.96% to 6.96%.
- Revenue Growth expectations are steady, moving from -3.37% to -3.37%.
- Net Profit Margin has fallen significantly, from 32.60% down to 25.58%.
- Future P/E has risen moderately, increasing from 7.46x to 10.16x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.